ProMIS Neurosciences Presents Preclinical Data Supporting Alzheimer's Vaccine Approach; Shows Strong Antibody Responses With No Pro-Inflammatory T Cell Responses Against AβO At AAIC 2024
Portfolio Pulse from Benzinga Newsdesk
ProMIS Neurosciences presented preclinical data at AAIC 2024 supporting their Alzheimer's vaccine approach, showing strong antibody responses without pro-inflammatory T cell responses against AβO.
July 30, 2024 | 12:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ProMIS Neurosciences presented promising preclinical data for their Alzheimer's vaccine at AAIC 2024, showing strong antibody responses without pro-inflammatory T cell responses against AβO.
The positive preclinical data presented by ProMIS Neurosciences at a major conference (AAIC 2024) is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100